Last updated: July 27, 2026

Application No. 18/025,205

BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA

Final Rejection

Filed

Mar 08, 2023

Priority

Sep 10, 2020 — provisional 63/076,792 +1 more

Examiner

LANDSMAN, ROBERT S

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Genmab A/S

OA Round

2 (Final)

Interview Optional

— +13.1% interview lift. Interview lift (+13.1%) is below the 15.0% threshold. A written response is recommended.

Based on 1264 resolved cases, 2023–2026

Examiner Intelligence

LANDSMAN, ROBERT S View full profile →

Grants 81% — above average

Career Allowance Rate

1029 granted / 1264 resolved

+21.4% vs TC avg

Moderate +13% lift

Without

With

+13.1%

Interview Lift

resolved cases with interview

Fast prosecutor

2y 2m

Avg Prosecution

49 currently pending

Career history

1295

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

24.3%

-15.7% vs TC avg

§102

10.8%

-29.2% vs TC avg

§112

27.1%

-12.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1264 resolved cases

Prosecution Timeline

Mar 08, 2023

Application Filed

Nov 13, 2025

Non-Final Rejection mailed

Feb 13, 2026

Response Filed

Apr 23, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/642,488

Patent 12674001

BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER

4y 3m to grant Granted Jul 07, 2026

19/302,560

Patent 12662545

MUSCLE-TARGETING COMPLEXES AND USES THEREOF

10m to grant Granted Jun 23, 2026

17/938,674

Patent 12649795

ANTI-IGF-1R ANTIBODIES AND USES THEREOF

3y 8m to grant Granted Jun 09, 2026

18/006,169

Patent 12637508

COMPOUNDS AND METHODS TARGETING HUMAN AND MOUSE INSL5

3y 4m to grant Granted May 26, 2026

18/844,732

Patent 12637513

METHOD OF TREATING CANCER BY ADMINISTERING AN INHIBITOR OF ERYTHROPOIETIN RECEPTOR ACTIVITY COMPRISING EITHER ERYTHROPOIETIN RECEPTOR OR ERYTHROPOIETIN PROTEIN

1y 8m to grant Granted May 26, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

81%

Grant Probability

94%

With Interview (+13.1%)

2y 2m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1264 resolved cases by this examiner. Grant probability derived from career allowance rate.